The study examined 29 patients who received the Regeneten implant and 28 patients who did not after a rotator cuff repair, according to a Sept. 14 company news release. Retear rates for those in the implant group was 3.5 percent at the 12-month follow-up and 25 percent in the group that did not have the Regeneten implant.
There were no differences in postoperative complications between the groups, according to the study.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
